O21 Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with ≥96 weeks of treatment von Nagraj, Praneeta, Thompson, Richard J, Durmaz, Özlem, Grammatikopoulos, Tassos, Di Giorgio, Angelo, Ni, Quanhong, Stein, Philip, Clemson, Christine, Sturm, Ekkehard

Volltext

Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole von Abbas, Richat, Childress, Ann C., Nagraj, Praneeta, Rolke, Richard, Berry, Sally A., Palumbo, Donna R.

Volltext

THU-317 - Real-world experience of Odevixibat in adults with genetic disorders of cholestasis von Trivedi, Palak, Borghi, Alberto, Engelmann, Cornelius, Hegade, Vinod, Hohenester, Simon, Joshi, Deepak, Monkelbaan, Jan F., Morgando, Anna, Nagraj, Praneeta, Valcheva, Velichka

Volltext

Real-world experience of Odevixibat in adults with genetic disorders of cholestasis von Trivedi, Palak, Borghi, Alberto, Engelmann, Cornelius, Hegade, Vinod, Hohenester, Simon, Joshi, Deepak, Monkelbaan, Jan F., Morgando, Anna, Nagraj, Praneeta, Valcheva, Velichka

Volltext

Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study von Wigal, Sharon B, Childress, Ann, Berry, Sally A, Belden, Heidi W, Chappell, Phillip, Wajsbrot, Dalia B, Nagraj, Praneeta, Abbas, Richat, Palumbo, Donna

Volltext

FDA’s Expedited Programs and Their Impact on the Availability of New Therapies von Damle, Nehar, Shah, Shilvi, Nagraj, Praneeta, Tabrizi, Pardis, Rodriguez, Gustavo Enrique, Bhambri, Rahul

Volltext

4.7 EFFICACY OF METHYLPHENIDATE EXTENDED-RELEASE CHEWABLE TABLETS IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: OPEN-LABEL, DOSE-OPTIMIZATION PERIOD OUTCOMES von Wigal, Sharon B., PhD, Childress, Ann Catherine, MD, Berry, Sally, MD, PhD, Belden, Heidi, PharmD, Chappell, Phillip B., MD, MBA, Wajsbrot, Dalia, Nagraj, Praneeta, Abbas, Richat, PhD, Palumbo, Donna R., PhD

Volltext